Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy
Tumor infiltrating lymphocyte therapy (TIL therapy) is one of the effective treatments for solid tumors. However, certain periods or sites of solid tumors are not amenable to surgical resection. Meanwhile, the abundant and dense extracellular matrix (ECM) and regulatory cells (e.g., regulatory T cel...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425001036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856733636788224 |
|---|---|
| author | Yishen Tian Jingxuan Li Na Yang Yang Zhao Jiancao Zuo Hang Xiong Yiwen Pan Li Xiao Min Su Feng Han Zhixu He Rong Hu |
| author_facet | Yishen Tian Jingxuan Li Na Yang Yang Zhao Jiancao Zuo Hang Xiong Yiwen Pan Li Xiao Min Su Feng Han Zhixu He Rong Hu |
| author_sort | Yishen Tian |
| collection | DOAJ |
| description | Tumor infiltrating lymphocyte therapy (TIL therapy) is one of the effective treatments for solid tumors. However, certain periods or sites of solid tumors are not amenable to surgical resection. Meanwhile, the abundant and dense extracellular matrix (ECM) and regulatory cells (e.g., regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC)) in solid tumors when infused back into the treatment will prevent T cell infiltration and proliferation, thus inhibiting the efficacy of this approach. In this study, a novel cell preparation was successfully developed by integrating microfluidic chip design with carbodiimide chemical modification. This preparation was surface modified with BTN2A2 antibodies and internally contained T cells isolated from the blood of tumor hosts, along with simulated collagen peptide CMP. Specifically, the cell preparation exerted its anti-tumor effects through multiple mechanisms: Firstly, the surface BTN2A2 antibodies effectively inhibited the proliferation of Tregs and MDSCs within the tumor microenvironment; Secondly, leveraging the T cell antigen receptors (TCRs) present in the blood T cells, which were similar to those of tumor-infiltrating lymphocytes, significantly enhanced their targeting and cytotoxic capabilities; Furthermore, the CMP component within the droplets effectively promoted the infiltration of T cells into tumor tissues. In the complex immunosuppressive microenvironment, the synergistic action of these components markedly enhanced the clearance efficacy of the immune system. Experimental results demonstrated that this cellular preparation exhibited promising therapeutic effects in both melanoma and pancreatic cancer models. This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects. |
| format | Article |
| id | doaj-art-4b5c9de997734e07907a7b53c1f04193 |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-4b5c9de997734e07907a7b53c1f041932025-02-12T05:31:42ZengElsevierMaterials Today Bio2590-00642025-04-0131101545Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapyYishen Tian0Jingxuan Li1Na Yang2Yang Zhao3Jiancao Zuo4Hang Xiong5Yiwen Pan6Li Xiao7Min Su8Feng Han9Zhixu He10Rong Hu11Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Key Laboratory for Research on Autoimmune Diseases of Higher Education Schools in Guizhou Province, Guiyang, 550025, China; Department of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaCenter for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Key Laboratory for Research on Autoimmune Diseases of Higher Education Schools in Guizhou Province, Guiyang, 550025, China; Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, ChinaCenter for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, ChinaDepartment of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaDepartment of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaDepartment of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaCenter for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Department of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaCenter for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Department of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaCenter for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Key Laboratory for Research on Autoimmune Diseases of Higher Education Schools in Guizhou Province, Guiyang, 550025, China; Department of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, ChinaDepartment of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China; Corresponding author.Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Department of Pediatric Hematology, The Affiliated Hospital of Guizhou Medical University, China; Corresponding author. Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China.Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China; Key Laboratory for Research on Autoimmune Diseases of Higher Education Schools in Guizhou Province, Guiyang, 550025, China; Department of Histology and Embryology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 550025, China; Corresponding author. Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, 550025, China.Tumor infiltrating lymphocyte therapy (TIL therapy) is one of the effective treatments for solid tumors. However, certain periods or sites of solid tumors are not amenable to surgical resection. Meanwhile, the abundant and dense extracellular matrix (ECM) and regulatory cells (e.g., regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC)) in solid tumors when infused back into the treatment will prevent T cell infiltration and proliferation, thus inhibiting the efficacy of this approach. In this study, a novel cell preparation was successfully developed by integrating microfluidic chip design with carbodiimide chemical modification. This preparation was surface modified with BTN2A2 antibodies and internally contained T cells isolated from the blood of tumor hosts, along with simulated collagen peptide CMP. Specifically, the cell preparation exerted its anti-tumor effects through multiple mechanisms: Firstly, the surface BTN2A2 antibodies effectively inhibited the proliferation of Tregs and MDSCs within the tumor microenvironment; Secondly, leveraging the T cell antigen receptors (TCRs) present in the blood T cells, which were similar to those of tumor-infiltrating lymphocytes, significantly enhanced their targeting and cytotoxic capabilities; Furthermore, the CMP component within the droplets effectively promoted the infiltration of T cells into tumor tissues. In the complex immunosuppressive microenvironment, the synergistic action of these components markedly enhanced the clearance efficacy of the immune system. Experimental results demonstrated that this cellular preparation exhibited promising therapeutic effects in both melanoma and pancreatic cancer models. This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.http://www.sciencedirect.com/science/article/pii/S2590006425001036Microfluidics chipGel dropletsAnti-BTN2A2TIL therapy |
| spellingShingle | Yishen Tian Jingxuan Li Na Yang Yang Zhao Jiancao Zuo Hang Xiong Yiwen Pan Li Xiao Min Su Feng Han Zhixu He Rong Hu Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy Materials Today Bio Microfluidics chip Gel droplets Anti-BTN2A2 TIL therapy |
| title | Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy |
| title_full | Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy |
| title_fullStr | Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy |
| title_full_unstemmed | Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy |
| title_short | Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy |
| title_sort | integrated microfluidics based construction of anti btn2a2 gel droplet cell preparations for non invasive tumor infiltrating lymphocyte therapy |
| topic | Microfluidics chip Gel droplets Anti-BTN2A2 TIL therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2590006425001036 |
| work_keys_str_mv | AT yishentian integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT jingxuanli integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT nayang integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT yangzhao integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT jiancaozuo integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT hangxiong integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT yiwenpan integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT lixiao integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT minsu integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT fenghan integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT zhixuhe integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy AT ronghu integratedmicrofluidicsbasedconstructionofantibtn2a2geldropletcellpreparationsfornoninvasivetumorinfiltratinglymphocytetherapy |